CCR2 and neoplasm: To further demonstrate the unique cross-priming capacity of APCs derived from CCR2+HSCs, we isolated antigen presenting cells directly from the tumors of mice receiving adoptive cellular therapy and used them as a cellular vaccine in recipient mice receiving DsRed+ tumor-reactive T cells.